Integral Health Asset Management Acquires 150,000 Shares in Dianthus Therapeutics

Got story updates? Submit your updates here. ›

Integral Health Asset Management LLC acquired a new stake of 150,000 shares in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the third quarter, according to a recent SEC filing. The shares were valued at approximately $5.9 million. Several other large investors have also added to or reduced their positions in Dianthus Therapeutics in recent quarters.

Why it matters

Dianthus Therapeutics is a clinical-stage biotech company developing complement therapeutics for severe autoimmune and inflammatory diseases. The acquisition of a significant stake by Integral Health Asset Management signals investor confidence in the company's pipeline and future potential.

The details

Integral Health Asset Management purchased 150,000 shares of Dianthus Therapeutics, representing a new stake in the company. Other major investors that have recently added or reduced positions in DNTH include Patient Square Capital LP, XTX Topco Ltd, Sio Capital Management LLC, and Vanguard Group Inc. Dianthus is currently advancing its lead candidate DNTH103, a monoclonal antibody, through Phase 2 clinical trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

• Integral Health Asset Management acquired the 150,000 shares during the third quarter of the year.
• Dianthus Therapeutics reported its latest quarterly earnings on March 9, 2026.